Viking Therapeutics (VKTX) Convertible Debt (2014 - 2018)

Viking Therapeutics has disclosed Convertible Debt across 5 years of filings, most recently posting $1.5 million for Q1 2018.

• In Q1 2018, Convertible Debt fell 59.6% year-over-year to $1.5 million; the TTM figure through Mar 2018 stood at $1.5 million (down 59.6% YoY), while the FY2017 annual figure was $1.5 million, changed 0.0% from the prior year.
• Convertible Debt came in at $1.5 million for Q1 2018 at Viking Therapeutics, roughly flat from $1.5 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $3.7 million in Q1 2017 to a low of $1.3 million in Q4 2014.
• Average Convertible Debt over 5 years is $1.8 million, with a median of $1.5 million recorded in 2016.
• Year-over-year, Convertible Debt jumped 119.57% in 2016 and slumped 59.6% in 2018.
• Over 5 years, Convertible Debt stood at $1.3 million in 2014, then surged by 70.2% to $2.2 million in 2015, then plunged by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
• Per Business Quant data, the three most recent Convertible Debt figures were $1.5 million in Q1 2018, $1.5 million in Q4 2017, and $1.5 million in Q3 2017.